申请人:TELIGENE LTD.
公开号:US20150126539A1
公开(公告)日:2015-05-07
The present invention is directed to novel quinazolines, their derivatives, pharmaceutically acceptable salts, solvates and hydrates thereof. The compounds and compositions of the present invention have protein kinases inhibitory activities and are expected to be useful for the treatment of protein kinases mediated diseases and conditions.
本发明涉及新型喹唑啉、其衍生物、药学上可接受的盐、溶剂物和水合物。本发明的化合物和组合物具有蛋白激酶抑制活性,并有望用于治疗蛋白激酶介导的疾病和病状。